| Not Yet Recruiting | Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. NCT07320963 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Recruiting | Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. NCT06059261 | Chongqing University Cancer Hospital | Phase 2 |
| Not Yet Recruiting | CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequa NCT07399158 | Fujian Cancer Hospital | — |
| Not Yet Recruiting | MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC NCT07331428 | Fujian Cancer Hospital | Phase 2 |
| Not Yet Recruiting | Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma NCT05912582 | Jiangsu Cancer Institute & Hospital | — |
| Recruiting | 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcino NCT07328854 | Ming-Yuan Chen | Phase 3 |
| Recruiting | TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma NCT06912711 | Sun Yat-sen University | Phase 2 |
| Recruiting | Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma NCT07000643 | Man Hu | Phase 3 |
| Not Yet Recruiting | Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer NCT06775756 | Fujian Cancer Hospital | Phase 3 |
| Recruiting | Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma NCT06682442 | University of California, San Francisco | N/A |
| Not Yet Recruiting | A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma NCT06781112 | Weiwei Zhang | Phase 2 |
| Recruiting | GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcino NCT06851247 | Sun Yat-sen University | Phase 2 |
| Recruiting | Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC NCT06752239 | Jiangxi Provincial Cancer Hospital | Phase 3 |
| Recruiting | A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma NCT06629597 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 3 |
| Recruiting | CD70-targeted immunoPET Imaging of Malignant Cancers NCT06852638 | RenJi Hospital | N/A |
| Not Yet Recruiting | Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal Carcinoma NCT06572293 | Fujian Cancer Hospital | N/A |
| Recruiting | ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients NCT06733948 | National University Hospital, Singapore | Phase 2 |
| Recruiting | Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinom NCT06592599 | Stanford University | Phase 2 |
| Not Yet Recruiting | Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam Therapy NCT06480903 | The Christie NHS Foundation Trust | — |
| Recruiting | Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients NCT06389201 | Affiliated Hospital of Nantong University | N/A |
| Recruiting | Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achi NCT06675214 | Sun Yat-sen University | Phase 3 |
| Recruiting | Adebrelimab and Chemoradiotherapy in High-risk LANPC NCT06349889 | Sun Yat-sen University | Phase 2 |
| Recruiting | Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherap NCT06197776 | Sun Yat-sen University | — |
| Recruiting | SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma NCT06323239 | Sun Yat-sen University | Phase 2 |
| Recruiting | Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Ca NCT06093061 | National Cancer Centre, Singapore | Phase 2 |
| Recruiting | Deep Learning-based sbORN Diagnostic Model NCT06463392 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Not Yet Recruiting | PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized Cli NCT06486220 | Yun-fei Xia | Phase 3 |
| Not Yet Recruiting | Assessing Manual Acupuncture's Impact on Mucositis From Nasopharynx Cancer Radiotherapy: A Visual Analogue Sca NCT06472024 | Indonesia University | N/A |
| Recruiting | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lu NCT06475300 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma NCT06455410 | Sun Yat-sen University | Phase 2 |
| Recruiting | Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A NCT06438627 | XIANG YANQUN | Phase 3 |
| Recruiting | Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma NCT06445088 | Sun Yat-sen University | — |
| Recruiting | Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma NCT06516133 | Sun Yat-sen University | Phase 3 |
| Recruiting | Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Met NCT06383780 | XIANG YANQUN | Phase 3 |
| Active Not Recruiting | Distribution of Bacteria in OME After Radiotherapy For NPC. NCT06523933 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Not Yet Recruiting | KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial NCT06370026 | Sun Yat-sen University | EARLY_Phase 1 |
| Not Yet Recruiting | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors NCT06383507 | Zhejiang University | Phase 1 |
| Not Yet Recruiting | Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma NCT06364826 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Individualized Elective Neck Irradiation in NPC Patients NCT06241612 | Sun Yat-sen University | Phase 3 |
| Recruiting | Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma. NCT06533267 | Sun Yat-sen University | N/A |
| Recruiting | TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma NCT06301165 | Sun Yat-sen University | Phase 2 |
| Recruiting | Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Ca NCT06277050 | Jiangxi Provincial Cancer Hospital | Phase 3 |
| Recruiting | De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for N NCT06313450 | Sun Yat-sen University | N/A |
| Recruiting | Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response NCT06239727 | Sun Yat-sen University | Phase 3 |
| Recruiting | Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-r NCT06259721 | Jiangxi Provincial Cancer Hospital | Phase 2 |
| Recruiting | Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis NCT06307314 | Nanfang Hospital, Southern Medical University | — |
| Recruiting | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Ca NCT05956587 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma NCT06321939 | Hunan Cancer Hospital | — |
| Recruiting | IC Plus Low-dose Radiation Plus Cadonilimab in LANPC NCT05941741 | Sun Yat-sen University | Phase 3 |
| Active Not Recruiting | Regulation of Blood-Brain Barrier Permeability by APOE Gene Polymorphism and Its Impact on Cognitive Function NCT06881225 | Sun Yat-sen University | — |
| Recruiting | The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC NCT06182657 | Jiangxi Provincial Cancer Hospital | — |
| Not Yet Recruiting | Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Sta NCT06095167 | Fujian Cancer Hospital | Phase 3 |
| Recruiting | Occurrence of Radiation-induced Otitis Media in Nasopharyngeal Carcinoma Patients After Intensity Modulated Ra NCT06170021 | Sun Yat-sen University | — |
| Active Not Recruiting | A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Na NCT06118333 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Unknown | KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial NCT06097793 | Kousai Bio Co., Ltd. | EARLY_Phase 1 |
| Unknown | Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and NCT06136962 | Fujian Cancer Hospital | — |
| Recruiting | Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC NCT06177301 | Fudan University | Phase 3 |
| Unknown | Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging NCT06129201 | Fifth Affiliated Hospital, Sun Yat-Sen University | — |
| Recruiting | Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal NCT06688760 | Ming-Yuan Chen | N/A |
| Recruiting | Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemo NCT06092957 | Sun Yat-sen University | Phase 3 |
| Recruiting | Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Ca NCT06055816 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma NCT05979961 | Sun Yat-sen University | Phase 3 |
| Recruiting | GNT Induction Treatment in Locally Advanced NPC NCT06026878 | Air Force Military Medical University, China | Phase 3 |
| Unknown | A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC NCT05949749 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Unknown | Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasophar NCT06032767 | Sun Yat-sen University | — |
| Recruiting | Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma NCT05780372 | Sun Yat-sen University | Phase 3 |
| Recruiting | Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma NCT05994170 | Zhongshan People's Hospital, Guangdong, China | N/A |
| Not Yet Recruiting | Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma NCT05898256 | Guangxi Medical University | Phase 1 / Phase 2 |
| Active Not Recruiting | Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) NCT05587374 | Sun Yat-sen University | Phase 3 |
| Recruiting | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies NCT05955105 | Innolake Biopharm | Phase 1 / Phase 2 |
| Unknown | Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis NCT05893810 | Jiangxi Provincial Cancer Hospital | Phase 3 |
| Terminated | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors NCT05563272 | Telix Pharmaceuticals (Innovations) Pty Ltd | Phase 2 |
| Completed | Methylation-specific PCR Test for Early Screening and Early Diagnosis of Nasopharyngeal Carcinoma NCT06367049 | Sun Yat-sen University | — |
| Completed | Retrospective Study on the Prediction of Radiation-induced Brain Injury in Patients With Nasopharyngeal Carcin NCT06244394 | Jiangsu Cancer Institute & Hospital | — |
| Unknown | Anrotinib and Tirelizumab in First-line Treatment of RM-NPC NCT05981157 | Zhongshan People's Hospital, Guangdong, China | Phase 2 |
| Recruiting | Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma NCT05877872 | Sun Yat-sen University | Phase 3 |
| Recruiting | Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma NCT05913414 | Sun Yat-sen University | Phase 2 |
| Recruiting | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC NCT05854849 | Sun Yat-sen University | Phase 3 |
| Active Not Recruiting | Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasophary NCT05869227 | XIANG YANQUN | Phase 3 |
| Recruiting | Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma NCT05813626 | Zhejiang Cancer Hospital | Phase 2 |
| Not Yet Recruiting | A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and NCT05780294 | Sun Yat-sen University | Phase 3 |
| Unknown | Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases NCT05771025 | Fudan University | N/A |
| Unknown | Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma NCT05790200 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Terminated | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) NCT05721222 | Genmab | Phase 1 / Phase 2 |
| Completed | EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyng NCT04509726 | Xinqiao Hospital of Chongqing | Phase 1 / Phase 2 |
| Recruiting | Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcino NCT05884983 | Zhongshan People's Hospital, Guangdong, China | — |
| Recruiting | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma NCT06019130 | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Phase 2 |
| Completed | Clincal Study of Reduced Target Radiotherapy in Nasopharyngeal Carcinoma NCT05741008 | First Affiliated Hospital of Kunming Medical University | N/A |
| Unknown | BGT007 Cell Treatment of Nasopharyngeal Carcinoma NCT05616468 | The Affiliated Hospital of Xuzhou Medical University | EARLY_Phase 1 |
| Recruiting | Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma NCT05587543 | Fudan University | EARLY_Phase 1 |
| Unknown | A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carci NCT05682703 | Nanfang Hospital, Southern Medical University | — |
| Not Yet Recruiting | A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcino NCT05622474 | Sun Yat-sen University | N/A |
| Active Not Recruiting | SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma NCT05524168 | Sun Yat-sen University | Phase 2 |
| Unknown | Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial NCT05531916 | Sun Yat-sen University | N/A |
| Recruiting | tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIB NCT05517135 | National Cancer Centre, Singapore | — |
| Recruiting | Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyng NCT05527470 | Wei Jiang | Phase 3 |
| Recruiting | Screening for Early Diagnosis of Nose Cancer NCT07019870 | National University Hospital, Singapore | N/A |
| Unknown | Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images NCT05627310 | Eye & ENT Hospital of Fudan University | — |
| Recruiting | Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnos NCT06529562 | Ming-Yuan Chen | N/A |
| Completed | TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Na NCT05563480 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advance NCT05544929 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC NCT05549466 | Sun Yat-sen University | Phase 2 |
| Unknown | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas NCT05415098 | Ascentage Pharma Group Inc. | Phase 1 |
| Unknown | Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines NCT05519956 | Fujian Cancer Hospital | Phase 3 |
| Recruiting | Optimization of Cervical Nodal CTV for Early and Medium Stage NPC NCT05145660 | Jun-Lin Yi, MD | Phase 3 |
| Unknown | Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metab NCT05547971 | Xiangya Hospital of Central South University | — |
| Completed | Hearing Impairment of Nasopharyngeal Carcinoma NCT05330169 | Guangxi Medical University | — |
| Unknown | CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC NCT05724355 | Sun Yat-sen University | Phase 2 |
| Unknown | PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemothe NCT06156878 | Fudan University | Phase 2 |
| Recruiting | Radiotherapy Combined With Endostatin and Capecitabine for NPC NCT05514275 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma NCT05707819 | Cancer Hospital of Guangxi Medical University | — |
| Unknown | Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma NCT05626829 | Jian Guan | Phase 2 |
| Active Not Recruiting | PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma NCT05340270 | Guangxi Medical University | Phase 2 |
| Recruiting | Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening NCT05447169 | Sun Yat-sen University | — |
| Unknown | Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: NCT05417139 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TN NCT05433597 | Sun Yat-sen University | Phase 2 / Phase 3 |
| Recruiting | Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma NCT05431764 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma NCT05211232 | Sun Yat-sen University | Phase 3 |
| Active Not Recruiting | KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine i NCT05294172 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 3 |
| Terminated | Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma NCT06248840 | Zeng Changhao | N/A |
| Recruiting | Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Na NCT05352321 | Sun Yat-sen University | N/A |
| Not Yet Recruiting | Umbrella Biomarker-Guided Therapy in NPC NCT04605562 | Sun Yat-sen University | Phase 2 |
| Terminated | Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma NCT06189482 | Zeng Changhao | N/A |
| Completed | Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients NCT05389306 | Sun Yat-sen University | N/A |
| Unknown | A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma NCT05576272 | Qilu Pharmaceutical Co., Ltd. | Phase 2 / Phase 3 |
| Active Not Recruiting | Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain NCT05304468 | Sun Yat-sen University | Phase 3 |
| Completed | Patients With Stage III-IVa Nasopharyngeal Carcinoma With or Without a Mobile Medical Platform Full-course Nut NCT05834712 | Sun Yat-sen University | N/A |
| Unknown | PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma NCT05341193 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Recruiting | Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Cl NCT05508347 | Sichuan Cancer Hospital and Research Institute | Phase 2 |
| Recruiting | Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinom NCT05342792 | Sun Yat-sen University | Phase 3 |
| Unknown | Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma NCT05097209 | Wei Jiang | Phase 2 |
| Recruiting | Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III NCT05340491 | Sun Yat-sen University | Phase 3 |
| Unknown | Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma NCT05201859 | Sun Yat-sen University | Phase 2 |
| Recruiting | Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcin NCT05290194 | Fifth Affiliated Hospital, Sun Yat-Sen University | Phase 2 |
| Completed | Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advance NCT05292027 | Sichuan Cancer Hospital and Research Institute | N/A |
| Recruiting | Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer NCT04825990 | Gruppo Oncologico del Nord-Ovest | Phase 2 |
| Unknown | PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal NCT05229315 | XIANG YANQUN | Phase 2 |
| Recruiting | Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma NCT05147844 | Xinqiao Hospital of Chongqing | Phase 2 |
| Active Not Recruiting | Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carci NCT05193617 | Sun Yat-sen University | Phase 2 |
| Unknown | EBV CAR-T Cells for Nasopharyngeal Carcinoma NCT05654077 | The Affiliated Hospital of Xuzhou Medical University | EARLY_Phase 1 |
| Unknown | Ovarian Function of Nasopharyngeal Carcinoma Women Survivors NCT05183724 | Sun Yat-sen University | — |
| Recruiting | Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA Aft NCT05772208 | Fudan University | Phase 3 |
| Recruiting | Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable NCT05674305 | Fudan University | Phase 3 |
| Recruiting | 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma NCT04813705 | Taizhou Hospital | Phase 2 |
| Unknown | Olfactory Change After Chemo-radiotherapy for Nasopharyngeal Carcinoma NCT05146050 | Sun Yat-sen University | — |
| Unknown | Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Imag NCT05202626 | Chinese Academy of Sciences | — |
| Recruiting | Immune Score Based Radiomics in Nasopharyngeal Carcinoma NCT05126160 | Zhejiang Cancer Hospital | — |
| Unknown | Asian Multicenter Prospective Study of ctDNA Sequencing NCT05099978 | National Cancer Center, Japan | — |
| Completed | Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcin NCT04996758 | Sun Yat-sen University | Phase 2 |
| Unknown | Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma NCT05092217 | Eye & ENT Hospital of Fudan University | Phase 2 |
| Terminated | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ R NCT05166577 | Viracta Therapeutics, Inc. | Phase 1 |
| Unknown | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma NCT05448885 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma NCT05020925 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyn NCT04436965 | Sun Yat-sen University | Phase 3 |
| Active Not Recruiting | A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma NCT04974398 | Akeso | Phase 3 |
| Unknown | Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma NCT05162872 | Sun Yat-sen University | Phase 2 |
| Unknown | Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements NCT05037357 | Sun Yat-sen University | — |
| Unknown | Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients NCT06442709 | Affiliated Hospital of Nantong University | N/A |
| Active Not Recruiting | PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Ca NCT04907370 | Sun Yat-sen University | Phase 3 |
| Unknown | Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma NCT04955886 | Fujian Cancer Hospital | Phase 2 |
| Unknown | Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carc NCT05177237 | Jiangxi Provincial Cancer Hospital | Phase 2 |
| Unknown | Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy NCT04978012 | Fudan University | Phase 2 |
| Completed | Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma NCT04823468 | Jinsheng Hong | N/A |
| Not Yet Recruiting | An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy f NCT04890522 | Sun Yat-sen University | Phase 2 / Phase 3 |
| Unknown | The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent o NCT04917770 | West China Hospital | Phase 2 |
| Completed | A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Re NCT04895345 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Unknown | The Association of hsCRP and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal Carcinoma NCT04303975 | Jiarong Chen, MD | — |
| Recruiting | Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carc NCT04944914 | Sun Yat-sen University | Phase 3 |
| Completed | The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC NCT04929080 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Completed | Nedaplatin in Treatment for Nasopharyngeal Carcinoma NCT04834206 | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Phase 2 |
| Unknown | Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC NCT04745741 | Fujian Cancer Hospital | — |
| Recruiting | Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma NCT04898374 | Kuwait Cancer Control Center | Phase 3 |
| Unknown | Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasoph NCT05008471 | Sun Yat-sen University | N/A |
| Unknown | Magnifying NBI for Occult NPC NCT04593186 | Chinese University of Hong Kong | N/A |
| Completed | Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC NCT04833257 | Sun Yat-sen University | Phase 2 |
| Terminated | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid NCT04272034 | Incyte Corporation | Phase 1 |
| Recruiting | Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma NCT04778956 | Sun Yat-sen University | Phase 3 |
| Recruiting | The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC NCT04830267 | Chongqing University Cancer Hospital | Phase 2 |
| Unknown | Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinom NCT04766359 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 3 |
| Unknown | The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasophary NCT04769076 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 |
| Completed | A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma NCT04736810 | Akeso | Phase 2 |
| Unknown | Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma NCT04143984 | Shanghai Proton and Heavy Ion Center | Phase 2 |
| Completed | Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma NCT04350190 | Wei Jiang | Phase 2 |
| Unknown | Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma NCT05232552 | Zhejiang Cancer Hospital | Phase 2 |
| Unknown | Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC NCT04557020 | Jiangxi Provincial Cancer Hospital | Phase 3 |
| Unknown | Comparison of Transdermal Fentanyl and Morphine for Oral Mucositis Pain in Nasopharyngeal Cancer Patients NCT04292990 | Jiarong Chen, MD | Phase 4 |
| Completed | Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal C NCT04636632 | Sun Yat-sen University | Phase 1 |
| Active Not Recruiting | Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma NCT04517214 | Fudan University | Phase 2 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid NCT04242199 | Incyte Corporation | Phase 1 |
| Unknown | Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasoph NCT04547088 | Sun Yat-sen University | Phase 2 |
| Unknown | A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irrad NCT04534855 | Sun Yat-sen University | Phase 2 |
| Unknown | Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasophary NCT04548271 | Sun Yat-sen University | Phase 2 |
| Recruiting | Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasoph NCT04448522 | Sun Yat-sen University | Phase 3 |
| Active Not Recruiting | Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma NCT04456322 | Sun Yat-sen University | Phase 3 |
| Recruiting | Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma NCT04437329 | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Phase 3 |
| Recruiting | Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma NCT04453813 | Sun Yat-sen University | Phase 3 |
| Unknown | Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospec NCT04992988 | Cancer Hospital of Guangxi Medical University | Phase 2 |
| Completed | uEXPLORER Total-body PET/CT in Nasopharyngeal Carcinoma NCT04394065 | Sun Yat-sen University | — |
| Unknown | Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC NCT04421469 | Fujian Cancer Hospital | Phase 2 |
| Completed | Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma NCT04227509 | Seoul National University Hospital | Phase 2 |
| Unknown | Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma NCT04447612 | The University of Hong Kong | Phase 2 |
| Unknown | Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcino NCT04414566 | West China Hospital | Phase 3 |
| Unknown | Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharynge NCT04319471 | Fujian Cancer Hospital | Phase 2 |
| Completed | To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients Wi NCT04387266 | Fujian Cancer Hospital | — |
| Unknown | To Evaluate Transoral Flexible Endoscope With Narrow Band Imaging in Nasopharyngeal Cancer NCT04419324 | Chinese University of Hong Kong | N/A |
| Not Yet Recruiting | Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma NCT04447326 | First Affiliated Hospital of Guangxi Medical University | Phase 2 |
| Unknown | EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR) NCT04072107 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma NCT04351282 | Fudan University | N/A |
| Unknown | Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. NCT04405622 | Sun Yat-sen University | Phase 2 |
| Unknown | Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients NCT04394091 | Sun Yat-sen University | — |
| Unknown | Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failur NCT04586088 | Sun Yat-sen University | Phase 2 |
| Completed | A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma NCT04220307 | Akeso | Phase 2 |
| Recruiting | Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC NCT04544969 | Sun Yat-sen University | — |
| Recruiting | Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City NCT04085900 | Zhongshan People's Hospital, Guangdong, China | — |
| Unknown | SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma NCT04282070 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma NCT03984357 | Sun Yat-sen University | Phase 2 |
| Completed | Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC NCT04396886 | The University of Hong Kong | Phase 2 |
| Active Not Recruiting | Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma NCT04223024 | Sun Yat-sen University | Phase 2 |
| Unknown | Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma NCT04221516 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Recruiting | Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma NCT04136886 | Sun Yat-sen University | Phase 3 |
| Unknown | Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients NCT03925090 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy NCT04384627 | Sun Yat-sen University | Phase 3 |
| Unknown | Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC NCT04220528 | Fujian Cancer Hospital | Phase 2 |
| Unknown | Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory So NCT04107142 | CytoMed Therapeutics Pte Ltd | Phase 1 |
| Unknown | Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Ca NCT04472403 | Sun Yat-sen University | — |
| Unknown | De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma NCT04158518 | Chaosu Hu | N/A |
| Unknown | Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Car NCT04764149 | Sun Yat-sen University | — |
| Unknown | Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients NCT03925896 | Sun Yat-sen University | Phase 1 |
| Unknown | A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasophary NCT04061278 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 3 |
| Unknown | Early Nutritional Intervention in NPC Patients Undergoing Concurrent Chemoradiotherapy NCT04810936 | Guangdong Provincial People's Hospital | N/A |
| Unknown | The Prognostic Value of Human Papilloma Virus in Nasopharyngeal Carcinoma NCT04014738 | Rambam Health Care Campus | — |
| Unknown | Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC NCT04015661 | Fuzhou General Hospital | Phase 2 |
| Unknown | Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related NCT03923842 | Gruppo Oncologico del Nord-Ovest | Phase 2 |
| Unknown | Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma. NCT04073784 | Sun Yat-sen University | Phase 1 |
| Completed | Prospective Comparisons of Clinical Trial and Real-world Outcomes in Nasopharyngeal Carcinoma NCT04108338 | Sun Yat-sen University | — |
| Unknown | Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal NCT03932266 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Completed | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum NCT03849469 | Xencor, Inc. | Phase 1 |
| Unknown | Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients NCT03855020 | Sun Yat-sen University | — |
| Active Not Recruiting | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tum NCT03891953 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA NCT03544099 | National Health Research Institutes, Taiwan | Phase 2 |
| Unknown | IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. NCT03854838 | Sun Yat-sen University | Phase 2 |
| Unknown | Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma NCT03915132 | Chinese Academy of Medical Sciences | Phase 2 |
| Completed | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) NCT03752398 | Xencor, Inc. | Phase 1 |
| Unknown | Proton Versus Photon Radiotherapy for Nasopharyngeal Carcinoma NCT04528394 | Shanghai Proton and Heavy Ion Center | Phase 2 |
| Completed | Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-li NCT03906058 | Sun Yat-sen University | Phase 2 |
| Unknown | Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma NCT03837808 | Sun Yat-sen University | Phase 3 |
| Terminated | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) NCT03682055 | Cullinan Therapeutics Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma NCT03840421 | Sun Yat-sen University | Phase 3 |
| Unknown | Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Na NCT04398056 | Sun Yat-sen University | Phase 2 |
| Completed | Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyng NCT04004871 | Guangxi Medical University | Phase 2 |
| Completed | A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma NCT03866967 | Akeso | Phase 2 |
| Completed | KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma NCT03848286 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 |
| Terminated | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal NCT03769467 | Atara Biotherapeutics | Phase 1 / Phase 2 |
| Terminated | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Canc NCT03809624 | Inhibrx Biosciences, Inc | Phase 1 |
| Completed | Using Massage of Maxillofacial and Oral Cavity to Prevent Radioactive Oral Mucositis NCT03788499 | Xinqiao Hospital of Chongqing | N/A |
| Recruiting | The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma NCT06268600 | Jiangxi Provincial Cancer Hospital | N/A |
| Unknown | Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis NCT03904225 | Zhejiang Cancer Hospital | Phase 2 |
| Unknown | Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcin NCT03707509 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Unknown | Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma NCT03668730 | Sun Yat-sen University | Phase 2 |
| Unknown | Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent NCT03708822 | Sun Yat-sen University | Phase 2 |
| Unknown | EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC NCT03648697 | Fujian Cancer Hospital | Phase 2 |
| Unknown | Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasoph NCT04522050 | Fifth Affiliated Hospital, Sun Yat-Sen University | Phase 1 |
| Unknown | Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis NCT03720340 | Zhejiang Cancer Hospital | Phase 3 |
| Completed | Combining PET/CT and EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced NPC NCT03601390 | Sun Yat-sen University | — |
| Unknown | Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma NCT03601975 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Completed | SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Che NCT03558191 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Completed | Intestinal Flora Sequencing for Nasopharyngeal Carcinoma NCT04094545 | The Third Xiangya Hospital of Central South University | — |
| Unknown | PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phas NCT05520814 | Sichuan Cancer Hospital and Research Institute | Phase 2 |
| Unknown | To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequ NCT03578575 | China Medical University Hospital | Phase 2 |
| Completed | Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal NCT03598218 | Wei Jiang | N/A |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 | Xencor, Inc. | Phase 1 |
| Unknown | Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma NCT03612219 | Wei Jiang | Phase 2 |
| Unknown | TOMO Versus IMRT in Nasopharyngeal Carcinoma Patients NCT03588403 | Zhejiang Cancer Hospital | — |
| Unknown | Radiation-associated Carotid Artery Disease in Patients With Nasopharyngeal Carcinoma NCT03568032 | Fudan University | — |
| Not Yet Recruiting | CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Rad NCT03529279 | Sun Yat-sen University | Phase 3 |
| Not Yet Recruiting | Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC NCT03503136 | Sun Yat-sen University | Phase 3 |
| Unknown | PET/MR in Locally Advanced Nasopharyngeal Carcinoma NCT03657017 | Zhejiang Cancer Hospital | N/A |
| Unknown | By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concur NCT03557112 | Guiyang Medical University | Phase 2 |
| Withdrawn | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previou NCT03390738 | The University of Hong Kong | Phase 2 |
| Unknown | Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma NCT03701451 | Wei Jiang | Phase 1 / Phase 2 |
| Completed | Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) NCT03267498 | Sue Yom | Phase 2 |
| Completed | Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sp NCT05020067 | Sun Yat-sen University | Phase 2 |
| Unknown | Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma NCT03344068 | Sun Yat-sen University | Phase 2 / Phase 3 |
| Unknown | Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients NCT03411954 | Zhejiang Cancer Hospital | — |
| Unknown | Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage NCT03403829 | Fudan University | Phase 3 |
| Unknown | Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC NCT03366415 | Chaosu Hu | Phase 3 |
| Unknown | Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients NCT03290820 | Sun Yat-sen University | Phase 2 |
| Unknown | To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal Ca NCT03346109 | Sun Yat-sen University | N/A |
| Active Not Recruiting | TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma NCT03306121 | Sun Yat-sen University | Phase 3 |
| Unknown | Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma NCT03321539 | Sun Yat-sen University | Phase 3 |
| Recruiting | Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients NCT03353467 | Sun Yat-sen University | N/A |
| Unknown | The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients NCT03240835 | Zhao Chong | — |
| Unknown | The Influence of Anxiety and Depression on Survival in Nasopharyngeal Carcinoma Patients NCT03290001 | Sun Yat-sen University | — |
| Unknown | Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) NCT03213587 | Zhejiang Cancer Hospital | Phase 2 |
| Completed | 18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study NCT04995185 | National Cancer Centre, Singapore | N/A |
| Completed | A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects NCT03121716 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Unknown | Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma NCT03087695 | Taichung Veterans General Hospital | — |
| Unknown | Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma NCT03097939 | National Cancer Centre, Singapore | Phase 2 |
| Completed | Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinom NCT03025958 | Zhejiang Cancer Hospital | Phase 2 |